TLX

Peers: LNTH AKTS DRTS IMNM NVS RADX CATX GEHC BWXT ASPI

Index	-
Market Cap	3.24B
Enterprise Value	3.57B
Income	33.62M
Sales	893.10M
Book/sh	1.44
Cash/sh	0.74
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1184
IPO	Nov 14, 2024

P/E	101.93
Forward P/E	209.13
PEG	-
P/S	3.63
P/B	6.64
P/C	12.88
P/FCF	-
EV/EBITDA	117.17
EV/Sales	4.00
Quick Ratio	1.85
Current Ratio	2.01
Debt/Eq	1.19
LT Debt/Eq	1.16
Option/Short	No / Yes

EPS (ttm)	0.09
EPS next Y	0.05
EPS next Q	0.06
EPS this Y	498.77%
EPS next Y	-45.84%
EPS next 5Y	-
EPS past 3/5Y	55.05% 29.38%
Sales past 3/5Y	93.54% 195.21%
EPS Y/Y TTM	198.49%
Sales Y/Y TTM	33.78%
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 19 AMC
EPS/Sales Surpr.	140.27% -0.55%

Insider Own	-
Insider Trans	-
Inst Own	0.99%
Inst Trans	0.29%
ROA	2.63%
ROE	7.39%
ROIC	3.20%
Gross Margin	52.13%
Oper. Margin	-0.81%
Profit Margin	3.76%
SMA20	-7.97%
SMA50	-14.31%
SMA200	-3.71%
Trades

Shs Outstand	334.13M
Shs Float	-
Short Float	-
Short Ratio	1.13
Short Interest	0.35M
52W High	13.11 -27.31%
52W Low	6.28 51.75%
Volatility	1.68% 1.81%
ATR (14)	0.41
RSI (14)	39.10
Beta	-0.17
Rel Volume	0.87
Avg Volume	311.86K
Volume	30,662

Perf Week	-0.10%
Perf Month	-13.13%
Perf Quarter	-3.64%
Perf Half Y	-13.36%
Perf YTD	27.24%
Perf Year	-10.35%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.29
Target Price	17.93
Prev Close	9.26
Price	9.53
Change %	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-17-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-18-25	Initiated	Citigroup	Buy	$22
Aug-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-03-25	Initiated	H.C. Wainwright	Buy	$23
Jun-05-25	Initiated	Wedbush	Outperform	$22
Nov-15-24	Initiated	UBS	Buy	$21

Oct-20-26 06:10PM	Telix Reports Third Quarter 2026 Financial Performance (GlobeNewswire) -10.13%
Oct-19-26 01:30AM	Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S. (GlobeNewswire)
Oct-14-26 01:00AM	Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM (PR Newswire)
Oct-09-26 08:38AM	Profound Medical and Telix Pharmaceuticals Partner to Advance Prostate Cancer Imaging and Treatment Education (InvestorsHub)
Oct-06-26 06:30AM	First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18) (GlobeNewswire)
06:13AM	Loading…
Sep-21-26 06:13AM	Telix to acquire ITM in deal worth up to $2.35bn (Pharmaceutical Technology) -10.17%
Sep-20-26 08:55PM	Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse (GlobeNewswire)
Sep-14-26 06:30AM	FDA Approves Telix's Brain Cancer Imaging Drug Pixclara (GlobeNewswire)
Sep-09-26 06:30AM	Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Sep-04-26 02:42PM	TLX Stock Clocks 5% Gain This Week Ahead Of FDA Decision On Brain Cancer Imaging Agent (Stocktwits)
Sep-02-26 09:56AM	Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway (InvestorsHub) +5.53%
Sep-01-26 06:18PM	Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway (GlobeNewswire)
Aug-31-26 06:21PM	Telix Appoints David Gill as Chair (GlobeNewswire)
Aug-20-26 03:01AM	Telix Pharmaceuticals Ltd (TLPPF) (H1 2026) Earnings Call Highlights: Revenue Surges 22% to ... (GuruFocus.com)
Aug-19-26 08:32PM	Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline (GlobeNewswire)
05:13AM	Loading…
05:13AM	Target leads retailer earnings on Wednesday (MarketWatch)
Aug-05-26 07:00AM	Telix to Host R&D Day in New York City on September 22, 2026 (GlobeNewswire)
Jul-30-26 06:37PM	Telix H1 2026 Results: Investor Webcast Notification (GlobeNewswire)
05:12AM	How Telix landed a $2.1 billion radiopharma deal with Regeneron (Pharma Voice)
Jul-21-26 05:00PM	TLX591-Tx ProstACT SELECT Study Published in Cancers Journal (GlobeNewswire) -5.49%
Jul-20-26 07:31PM	Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress (GlobeNewswire)
05:00PM	Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer (GlobeNewswire)
Jul-16-26 06:12AM	Telix opens radiopharmaceutical facility in Australia for cancer treatment (Pharmaceutical Technology)
Jul-15-26 04:20PM	First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer (GlobeNewswire)
Jul-01-26 09:31PM	FDA Alignment to Advance ProstACT Global Phase 3 Trial (GlobeNewswire)
Jun-22-26 05:40PM	Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions (GlobeNewswire)
Jun-02-26 07:00AM	Telix and United Imaging Announce Strategic Theranostics Collaboration (GlobeNewswire)
Jun-01-26 05:00PM	ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 (GlobeNewswire)
May-27-26 07:00AM	Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences (GlobeNewswire)
May-18-26 05:00PM	IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing (GlobeNewswire)
06:30AM	Loading…
May-15-26 06:30AM	Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches (GlobeNewswire)
May-04-26 05:00PM	New Publication Demonstrates TLX250-Px (Zircaix) Potential in Diagnosing Kidney Cancers Beyond ccRCC (GlobeNewswire)
Apr-30-26 09:07PM	TLX101-Px (Pixlumi) MAA Accepted in Europe (PR Newswire) +5.47%
Apr-29-26 05:00PM	OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer (GlobeNewswire)
Apr-27-26 07:27PM	Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next-Generation Portfolio Approach (GlobeNewswire)
Apr-21-26 04:49PM	ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026 (GlobeNewswire)
Apr-14-26 07:04PM	Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma (GlobeNewswire)
04:34AM	Telix Refinances Convertible Bonds (PR Newswire)
Apr-13-26 06:30AM	Telix and Regeneron Announce Strategic Radiopharma Collaboration (GlobeNewswire) +6.64%
Apr-09-26 06:51PM	FDA Accepts NDA for TLX101-Px (Pixclara) (GlobeNewswire) +7.55%
Apr-08-26 06:44PM	Telix Strengthens Board with Additional Director Appointments (GlobeNewswire)
Apr-06-26 07:37PM	Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement (GlobeNewswire) +5.94%
Apr-01-26 07:53PM	Telix Appoints David Gill as Non-Executive Director (GlobeNewswire)
Mar-15-26 05:25PM	Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara) Brain Cancer Imaging Candidate (GlobeNewswire)
Mar-10-26 07:01AM	Why Is Telix Pharmaceuticals Stock Gaining Tuesday? (Benzinga) +5.47%
Mar-09-26 07:19PM	ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives (GlobeNewswire)
Mar-01-26 10:33PM	Telix Pharmaceuticals Highlights $1B Revenue Track, Pixclara Resubmission, PSMA Growth at Oppenheimer Conf. (MarketBeat)
05:57PM	Investor Education Webinar (GlobeNewswire)
Feb-27-26 07:00AM	Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging (GlobeNewswire)
03:40AM	Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why (Insider Monkey)
Feb-20-26 07:00AM	Telix to Participate in Oppenheimer and TD Cowen Conferences (GlobeNewswire) +14.61%
12:55AM	Telix Pharma FY25 Adj. EBITDA Declines; Revenue Up 56% (RTT News)
12:04AM	Telix Pharmaceuticals Ltd (TLPPF) Full Year 2025 Earnings Call Highlights: Robust Revenue ... (GuruFocus.com)
Feb-19-26 11:08PM	Telix Pharmaceuticals H2 Earnings Call Highlights (MarketBeat)
07:02PM	FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment (GlobeNewswire)
Feb-17-26 04:55PM	Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging (GlobeNewswire)
Feb-03-26 04:35PM	Telix Full Year Results 2025 Investor Webcast Notification (GlobeNewswire)
Jan-21-26 02:15PM	Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure (Benzinga) -5.43%
Jan-20-26 07:00AM	Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch (GlobeNewswire)
Jan-16-26 02:19PM	First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study (GlobeNewswire)
Jan-09-26 03:16AM	Here's What Analysts Think About Telix Pharmaceuticals (TLX) (Insider Monkey)
Jan-08-26 06:00AM	Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-26 09:00AM	Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
Dec-29-25 02:41AM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX (PR Newswire)
Dec-21-25 04:38PM	Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions (GlobeNewswire)
Dec-18-25 05:23AM	Telix Pharmaceuticals Limited (TLX)'s Commercial Progress Meets a Cautious Outlook (Insider Monkey)
Dec-16-25 03:30PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Dec-15-25 12:34PM	Telix Pharma (TLX) Makes Progress With New Study (Insider Monkey)
Dec-10-25 07:00AM	Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration (GlobeNewswire)
Dec-08-25 04:01PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Dec-05-25 03:30PM	Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
Dec-01-25 07:06PM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Nov-28-25 05:25PM	Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire)
Nov-25-25 08:03PM	Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire) +5.13%
08:45AM	Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
Nov-19-25 02:00PM	ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses (GlobeNewswire)
Nov-18-25 03:03PM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX (PR Newswire)
Nov-13-25 08:25AM	Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately (PR Newswire)
Nov-11-25 05:36PM	Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights TLX (Business Wire)
Nov-05-25 06:00AM	Telix to Participate in UBS and Jefferies Global Healthcare Conferences (GlobeNewswire)
Oct-23-25 07:00AM	TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging (GlobeNewswire)
Oct-22-25 04:00PM	Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain (GlobeNewswire)
Oct-14-25 02:22AM	Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded (GlobeNewswire) +5.24%
Sep-30-25 04:12AM	Telix Pharmaceuticals (TLX) Limited Receives Transitional Pass-Through payment status for Gozellix (Insider Monkey)
Sep-23-25 10:15AM	CMS Grants Transitional Pass-Through Status for Gozellix (GlobeNewswire) +8.76%
Sep-18-25 10:40AM	Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials (Insider Monkey)
Sep-16-25 09:47AM	Telix Pharmaceuticals Begins Phase 3 Trial for Prostate Cancer Diagnostics (Insider Monkey)
Sep-09-25 07:00PM	Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis (GlobeNewswire)
Aug-26-25 07:00AM	Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-20-25 08:22PM	Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth (GlobeNewswire) +10.21%
05:23AM	Target, Lowe's and TJX earnings to give update on consumer spending (MarketWatch)
04:36AM	Stock Market Today: Nasdaq futures lead Dow and S&P 500 lower as rotation out of big tech continues; Target earnings on tap; traders await Powell's Friday speech. (MarketWatch)
Jul-29-25 06:58PM	Telix H1 2025 Results: Investor Webcast Notification (GlobeNewswire)
Jul-22-25 04:39AM	Telix Pharma Q2 Revenue Up 63%; Confirms FY25 Revenue Guidance (RTT News)
04:06AM	Telix Reports $204M Revenue, Up 63% YOY (GlobeNewswire)
Jul-09-25 06:45PM	Gozellix Receives Permanent HCPCS Code (GlobeNewswire) +7.84%
Jul-03-25 09:41AM	Meta upgraded, PNC Financial downgraded: Wall Street's top analyst calls (The Fly)
Jun-29-25 01:28PM	Telix Pharmaceuticals (TLX) Announces That US FDA Approves Label Expansion for Illuccix (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Darren Charlton	Group Chief Financial Officer	Sep 07 '26	Buy	9.66	2,071	19,998	13,992	Sep 14 07:20 PM
Behrenbruch Christian	MD & Group CEO	Apr 28 '26	Buy	14.48	34,500	499,560	20,709,500	May 06 09:32 PM
Behrenbruch Christian	MD & Group CEO	Apr 29 '26	Buy	14.87	33,435	497,178	20,742,935	May 06 09:32 PM
Smith Darren Charlton	Group Chief Financial Officer	Mar 29 '26	Option Exercise	0.00	1,111	0	11,921	Apr 01 07:14 PM

Telix Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development and commercialization of several clinical-stage oncology assets. The firm operates through the following segments: Therapeutics (Tx), Precision Medicine (Px), and Telix Manufacturing Solutions (TMS). The Tx segment focuses on development of targeted radionuclide therapies for urologic and neurologic oncology, and other solid tumors. The Px segment includes provision of diagnostic imaging solutions to market and expanding into new geographies and indications. The TMS segment comprises of costs to operate the firm's facilities and assets. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East and Africa. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in North Melbourne, Australia.

DPhil(Oxon)Dr. Christian P. Behrenbruch BEng(Hons)

FCPAMr. Darren Smith B.Bus.

Group Chief Operating OfficerMr. Darren Patti Pharm.D.

M.D.Dr. David N. Cade M.B.A.

SVP of Research & DevelopmentDr. Paul Schaffer

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Telix Pharmaceuticals Ltd ADR

Upgrade your Finviz experience